Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03651752 · ClinicalTrials.gov registry record · Phase 3
DPCP for the Treatment of Alopecia Areata
A Phase 3 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT03651752: Clinical Trial Phase 3 study, sponsored by University of Minnesota.
NCT03651752 is a Phase 3 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 4 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03651752, a Phase 3 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is an open labeled study to determine the response and characteristics, safety and efficacy, of the proprietary DPCP ointment composition as a topical immunotherapeutic agent for the treatment of extensive alopecia areata.
Primary Outcome
Efficacy will be assessed as follows; a. Severity of Alopecia tool (SALT) score: Percentage of hair loss on the scalp will be determined using he SALT score, a global alopecia areata severity score based on scalp hair loss. The SALT score is calculated by visually examining four descrete areas of the scalp, measuring the percentage of terminal hair loss in each area. b. Scalp Photograhpy. c. Hair pull tests (positive or negative)
Interventions
- DRUG Diphenylcyclopropenone (DPCP) Ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2024-09-01 |
| Phase | Phase 3 |
Why NCT03651752 stopped before completion
NCT03651752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Diphenylcyclopropenone (DPCP) Ointment is the first listed.
NCT03651752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03651752 about?
NCT03651752 is a clinical study titled "DPCP for the Treatment of Alopecia Areata". This is an open labeled study to determine the response and characteristics, safety and efficacy, of the proprietary DPCP ointment composition as a topical immunotherapeutic agent for the treatment of extensive alopecia areata.
What is the current status of trial NCT03651752?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2024-04-01. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT03651752?
The interventions under investigation include: Diphenylcyclopropenone (DPCP) Ointment (DRUG).
Who is sponsoring clinical trial NCT03651752?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03651752's enrollment target sits among peer trials
4 1998th of 2000 higher than 2 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI